Investing.com
Krystal Biotech CEO Krishnan sells $8.89 million in stock By Investing.com
Krystal Biotech CEO Krishnan sells $8.89 million in stock
TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones By Investing.com
TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones
XRP Climbs 11% As Investors Gain Confidence By Investing.com
XRP Climbs 11% As Investors Gain Confidence
Earnings call transcript: Legend Biotech Q4 2024 sees strong CARVICTI growth By Investing.com
Earnings call transcript: Legend Biotech Q4 2024 sees strong CARVICTI growth
Jefferies sets Krystal Biotech stock Buy rating, $245 target By Investing.com
Jefferies sets Krystal Biotech stock Buy rating, $245 target
Krystal Biotech chief accounting officer sells $131,415 in stock By Investing.com
Krystal Biotech chief accounting officer sells $131,415 in stock
Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com
Karyopharm Therapeutics Inc.'s SWOT analysis: biotech firm's stock faces pivotal year
N2OFF to acquire biotech firm MitoCareX in strategic move By Investing.com
N2OFF to acquire biotech firm MitoCareX in strategic move
Regeneron’s SWOT analysis: biotech stock faces eylea challenges, pipeline promise By Investing.com
Regeneron's SWOT analysis: biotech stock faces eylea challenges, pipeline promise
XRP Falls 10% In Selloff By Investing.com
XRP Falls 10% In Selloff
EU imposes new sanctions on Russia, targets cryptocurrency exchange By Investing.com
EU imposes new sanctions on Russia, targets cryptocurrency exchange
Merus N.V.’s SWOT analysis: biotech firm’s stock poised for growth amid clinical trials
Merus N.V. (NASDAQ:MRUS), a biotechnology company specializing in innovative antibody-based therapies with a market capitalization of $2.75 billion,…
Rezolute’s SWOT analysis: biotech stock advances on ersodetug trials
Rezolute , Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company, is making significant strides in the development of its lead…
Oncolytics Biotech faces Nasdaq delisting over share price By Investing.com
Oncolytics Biotech faces Nasdaq delisting over share price
Earnings call transcript: Odfjell Technology Q4 2024 reports strong revenue growth
Odfjell Technology Ltd (OTL) reported robust financial results for the fourth quarter of 2024, showcasing a significant revenue…
